-
E-mail
lei@guiyisci.com
-
Phone
13651923355
-
Address
Room 502, No. 25, Lane 1288, Luoning Road, Baoshan District, Shanghai
Shanghai Siyi Biochemical Technology Co., Ltd
ASMS 2024 | SCIEX releases new high-throughput screening mass spectrometry Echo MS+system
Date: 2024-07-02Read: 0
At the 2024 ASMS (American Society for Mass Spectrometry Annual Meeting), SCIEX, a global innovator in life science analysis technology, officially released the new generation Echo MS+system. The system adheres to high-speed acoustic droplet excitation technology (AEMS) and open port interface technology (OPI), while innovating automatic cleaning function to enhance instrument durability. Continued compatibility with triple quadrupole mass spectrometry SCIEX Triple Quad at the mass spectrometry end ™ 6500+system, while expanding high-resolution time-of-flight mass spectrometry SCIEX ZenoTOF ® 7600 system. Multiple mass spectrometry options can further expand the application scope of high-throughput screening, providing qualitative and quantitative analysis results.
New generation SCIEX Echo ™ The MS+system combines high-speed acoustic droplet excitation technology (AEMS) with high-resolution time-of-flight mass spectrometry (SCIEX ZenoTOF) ® The combination of the 7600 system further enhances the high-throughput screening capability.
The SCIEX Echo MS+system solves the key pain point in high-throughput screening applications - a large amount of method development work, which can be flexibly applied in the workflow of large molecule and small molecule research. Compared with other analytical tools, the support of high-resolution mass spectrometry systems improves data selectivity and sensitivity while meeting high-throughput screening requirements. Taking into account instrument characteristics such as analysis speed, data quality, and small sample reagent consumption, the SCIEX Echo MS+system can help scientists reduce the time required to make critical decisions, lower costs, and mitigate risks.
It is precisely because the SCIEX Echo MS+system has such scalability that researchers can make quick and confident decisions in early applications such as target bioactive compound screening and lead compound optimization. This will help accelerate drug development cycles and reduce the probability of false positives or false negatives.